PRODUCTS SERVICES COMPANY CONTACT FAQ

Search Dictionary Mobile

Login

Richard E Chaisson Selected Research

Tuberculosis

12/2007	Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model.
07/2007	The impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro, Brazil.
04/2006	Weekly rifapentine/isoniazid or daily rifampin/pyrazinamide for latent tuberculosis in household contacts.
06/2005	Effect of routine isoniazid preventive therapy on tuberculosis incidence among HIV-infected men in South Africa: a novel randomized incremental recruitment study.
11/2004	Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis.
08/2004	Hepatotoxicity of rifampin and pyrazinamide in the treatment of latent tuberculosis infection in HIV-infected persons: is it different than in HIV-uninfected persons?
02/2004	Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis.
06/2003	Human immunodeficiency virus-1 RNA levels and CD4 lymphocyte counts, during treatment for active tuberculosis, in South African patients.
06/2003	Tuberculosis chemotherapy: still a double-edged sword.
09/2002	Comparison of C(18)-carboxypropylbetaine and standard N-acetyl-L-cysteine-NaOH processing of respiratory specimens for increasing tuberculosis smear sensitivity in Brazil.
07/2002	Safety and tolerability of intermittent rifampin/pyrazinamide for the treatment of latent tuberculosis infection in prisoners.
04/2002	Declining tuberculosis and drug resistance rate among HIV-positive patients at an Italian teaching hospital in the era of highly active antiretroviral therapy.

Articles by Research Topic

Disease

12	Tuberculosis 12/2007 - 04/2002
6	Infection 08/2004 - 01/2002
3	HIV Infections (HIV Infection) 10/2008 - 04/2003
2	Disease Progression 03/2006 - 03/2003
1	Extensively Drug-Resistant Tuberculosis 03/2007
1	Pulmonary Tuberculosis 08/2006
1	Hyperglycemia 08/2003
1	Drug Toxicity (Drug Safety) 03/2003
1	Hepatitis C 01/2002

Drug/Important Bio-Agent (IBA)

3	Isoniazid (Ftivazide)FDA LinkGeneric 07/2007 - 06/2005
3	moxifloxacin (Avelox)FDA Link 08/2006 - 02/2004
3	Pyrazinamide FDA LinkGeneric 04/2006 - 07/2002
3	Rifampin (Rifampicin)FDA LinkGeneric 04/2006 - 07/2002
2	efavirenz (Sustiva)FDA Link 10/2008 - 01/2002
2	Nevirapine (Viramune)FDA Link 10/2008 - 01/2002
2	rifapentine (Priftin)FDA Link 12/2007 - 04/2006
1	Ethambutol (Myambutol)FDA LinkGeneric 08/2006
1	RifamycinsIBA 10/2003
1	RNA (Ribonucleic Acid)IBA 06/2003
1	Heroin (Diamorphine)IBA 04/2003
1	Buprenorphine (Subutex)FDA LinkGeneric 04/2003
1	Methadone (Dolophine)FDA LinkGeneric 04/2003
1	Clonidine (ST 155)FDA LinkGeneric 04/2003
1	C(18)-carboxypropylbetaineIBA 09/2002
1	Acetylcysteine (Siran)FDA LinkGeneric 09/2002
1	Interferon-gamma (Interferon, gamma)IBA 06/2002

Therapy/Procedure

5	Highly Active Antiretroviral Therapy (HAART) 03/2006 - 04/2002
1	Magic 03/2007
1	Drug Therapy (Chemotherapy) 06/2003